Victory Capital Management Boosts Stake in BridgeBio Pharma

Institutional investor increases position in biotech firm by 42% in Q3

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Victory Capital Management Inc. grew its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 42% during the third quarter, according to a recent SEC filing. The firm now owns 479,680 shares of the company's stock, worth $24.9 million at the end of the quarter.

Why it matters

BridgeBio Pharma is a clinical-stage biotech company focused on developing treatments for genetic diseases and cancers. The increase in ownership by Victory Capital Management, a major institutional investor, signals continued confidence in the company's pipeline and future prospects.

The details

Victory Capital Management acquired an additional 141,800 shares of BridgeBio Pharma during the third quarter, bringing its total position to 479,680 shares. This represents about 0.25% of the company's outstanding stock. The investment firm cited BridgeBio's promising drug candidates and growth potential as reasons for boosting its stake in the biotech.

  • Victory Capital Management filed its Q3 2026 holdings report with the SEC on March 10, 2026.

The players

Victory Capital Management Inc.

A major institutional investment management firm that oversees over $150 billion in client assets.

BridgeBio Pharma, Inc.

A clinical-stage biopharmaceutical company focused on developing treatments for genetic diseases and cancers.

Got photos? Submit your photos here. ›

The takeaway

Victory Capital Management's increased stake in BridgeBio Pharma suggests the investment firm sees significant long-term potential in the biotech company's drug pipeline and business model. This vote of confidence from a major institutional investor could signal positive things to come for BridgeBio Pharma.